Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia

Herein, we present the final report of a single-center, prospective phase II study evaluating ibrutinib 420 mg once daily in 30 treatment-naive patients with Waldenstrom macroglobulinemia (WM). The present study is registered with ClinicalTrials.Gov (NCT02604511). With a median follow-up of 50 month...

Descripción completa

Detalles Bibliográficos
Autores principales: Castillo, Jorge J., Meid, Kirsten, Gustine, Joshua N., Leventoff, Carly, White, Timothy, Flynn, Catherine A., Sarosiek, Shayna, Demos, Maria G., Guerrera, Maria L., Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Xu, Lian, Yang, Guang, Branagan, Andrew R., O’Donnell, Elizabeth, Raje, Noopur, Yee, Andrew J., Patterson, Christopher J., Hunter, Zachary R., Treon, Steven P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807393/
https://www.ncbi.nlm.nih.gov/pubmed/34531537
http://dx.doi.org/10.1038/s41375-021-01417-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807393/
https://www.ncbi.nlm.nih.gov/pubmed/34531537
http://dx.doi.org/10.1038/s41375-021-01417-9

Ejemplares similares